Nigeria’s growing capacity for advanced fertility treatment is attracting patients from across Africa and the Nigerian diaspora, creating an emerging medical tourism opportunity while exposing a major gap in health insurance coverage for Nigerians seeking assisted reproductive care.
Fertility specialists say Nigeria has developed the capacity to provide sophisticated in-vitro fertilisation and other assisted reproductive technologies at prices that remain comparatively lower than those in many countries where patients travel from.
But the experts warn that high treatment costs continue to put IVF beyond the reach of many Nigerians, with imported fertility drugs and medical supplies accounting for a significant part of the expense.
The development presents a potentially significant opportunity for the insurance industry, particularly if insurers and policymakers move towards broader coverage of fertility treatment.
IVF creates new insurance opportunity
The President of the Association for Fertility and Reproductive Health, Prof. Preye Fiebai, said Nigeria was experiencing what he described as “reverse medical tourism”, with patients travelling into the country for fertility treatment because of its relatively competitive costs.
The trend means Nigeria’s fertility sector is increasingly becoming part of the country’s broader healthcare economy.
For insurers, however, the more immediate issue is domestic access.
While foreign patients may be able to take advantage of Nigeria’s lower treatment costs, many Nigerians requiring IVF still struggle to finance the procedures themselves.
Fiebai called for greater support from government and health insurance providers, arguing that fertility care should receive greater attention within efforts to achieve universal healthcare.
High costs keep Nigerians out
The cost of IVF remains one of the biggest barriers to access.
According to Fiebai, much of the medication and other materials required for fertility treatment are imported, increasing the cost of procedures and exposing providers and patients to exchange-rate and supply-chain pressures.
The dependence on imported inputs also creates an opening for longer-term investment in local pharmaceutical and medical production.
Reducing those costs could potentially make fertility treatment more accessible while also strengthening Nigeria’s competitiveness as a destination for reproductive healthcare.
Insurance coverage could change the market
The call for greater health insurance coverage could have far-reaching implications for Nigeria’s insurance industry.
If fertility treatment becomes more widely incorporated into health insurance packages, insurers could gain access to a growing specialist healthcare market while helping spread the financial burden of expensive procedures across a broader pool of policyholders.
Such products would, however, require careful underwriting and benefit design because fertility treatment can involve multiple procedures, medication costs and varying treatment outcomes.
The growing demand could also encourage insurers to develop specialised reproductive-health benefits rather than treating fertility services as an optional or largely excluded category.
Nigeria has treatment capacity
Despite the affordability challenge, fertility experts say Nigeria is no longer limited to basic reproductive procedures.
Fiebai said the country had progressed from rudimentary fertility services to providing some of the most advanced reproductive technologies available internationally.
That capacity, combined with Nigeria’s large population, could position the country as an important reproductive-health hub in Africa.
The opportunity extends beyond IVF itself, potentially supporting specialist clinics, pharmaceutical supply chains, medical research, diagnostics and other healthcare services.
Poor data could hold back investment
One of the industry’s less visible challenges is inadequate data.
Fiebai said poor reporting of fertility procedures meant the size and economic significance of Nigeria’s IVF market was not being properly captured.
He argued that better data would make the country more attractive to pharmaceutical companies and other investors seeking markets with significant treatment volumes.
For insurers, reliable data would be equally important.
Accurate information on the number of treatment cycles, patient demographics, treatment outcomes and associated costs would help insurers assess risk and develop sustainable fertility-related products.
Experts demand stronger regulation
The fertility industry is also calling for stronger regulation of assisted reproductive technology.
Fiebai disclosed that fertility practitioners had been engaging with the National Assembly on legislation governing assisted reproductive treatment.
Clearer rules could provide greater certainty for patients, healthcare providers, insurers and investors as the sector expands.
For insurers in particular, a stronger regulatory framework could help define acceptable standards of care, provider accountability and the scope of treatments that could eventually qualify for insurance coverage.
Local production could lower insurance costs
Reducing Nigeria’s dependence on imported fertility drugs could have implications beyond the medical sector.
Lower treatment costs could reduce the financial burden associated with fertility benefits and potentially make broader insurance coverage more commercially viable.
It could also reduce the exposure of fertility providers and patients to currency fluctuations and international supply disruptions.
With Nigeria simultaneously trying to deepen local production and expand health insurance coverage, fertility treatment sits at the intersection of two major healthcare policy challenges.
A market insurers may no longer ignore
Nigeria’s emergence as a destination for relatively affordable IVF is an unexpected development in the country’s medical tourism story.
But the bigger opportunity may be at home.
As fertility treatment becomes more advanced and demand grows, the absence of affordable insurance protection risks leaving a large proportion of Nigerians outside the market.
For insurers, the sector presents both a challenge and an opportunity: designing products that make expensive fertility procedures more accessible without creating unsustainable claims exposure.
If policymakers, healthcare providers and insurers can address affordability, regulation, data and local production, Nigeria’s fertility industry could evolve from a specialist medical service into a significant component of the country’s healthcare and insurance market.
